JAK/STAT pathway modulation: Does it work in dermatology?

被引：26

作者：

Gunduz, Ozgur ^{[1
]}

机构：

[1] Kirikkale Univ, Fac Med, Dept Dermatol & Venerol, Tahsin Duru Ave 14, TR-71450 Yahsihan, Kirikkale, Turkey

来源：

DERMATOLOGIC THERAPY | 2019年 / 32卷 / 03期

关键词：

alopecia areata; anitinflammatory; atopic dermatitis; immunomodulation; Jakinibs; Janus kinase (JAK); psoriasis; signal transducer and activator of transcription (STAT); DISEASE; JAKS;

D O I：

10.1111/dth.12903

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

Janus kinase-signal transducer and activator of transcription (JAK/STAT)-is an intracellular signaling pathway, which plays a key role in downstream transmission of extracellular signals from cell membrane to the cell nucleus. This pathway is activated by cytokines, which participate in inflammation, innate and acquired immune responses, and also cell growth. Recent studies point out possible disturbances in JAK/STAT pathway in various inflammatory and autoimmune skin diseases, such as atopic dermatitis, psoriasis, alopecia areata. Several molecules that modulate-inhibit-this pathway are currently under investigation for the evaluation of their clinical use in dermatological diseases. A brief overview of the therapeutical use of JAK/STAT inhibitors in dermatology will be provided here.

引用

收藏

页数：3

相关论文

共 16 条

[1] Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial [J].

Bachelez, Herve ;

van de Kerkhof, Peter C. M. ;

Strohal, Robert ;

Kubanov, Alexey ;

Valenzuela, Fernando ;

Lee, Joo-Heung ;

Yakusevich, Vladimir ;

Chimenti, Sergio ;

Papacharalambous, Jocelyne ;

Proulx, James ;

Gupta, Pankaj ;

Tan, Huaming ;

Tawadrous, Margaret ;

Valdez, Hernan ;

Wolk, Robert .

LANCET, 2015, 386 (9993) :552-561

[2]

Cinats A., 2018, SKIN THERAPY LETT, V23, P3

[3] Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata [J].

Crispin, Milene Kennedy ;

Ko, Justin M. ;

Craiglow, Brittany G. ;

Li, Shufeng ;

Shankar, Gautam ;

Urban, Jennifer R. ;

Chen, James C. ;

Cerise, Jane E. ;

Jabbari, Ali ;

Winge, Marten C. G. ;

Marinkovich, M. Peter ;

Christiano, Angela M. ;

Oro, Anthony E. ;

King, Brett A. .

JCI INSIGHT, 2016, 1 (15)

[4] JAK inhibitors in dermatology: The promise of a new drug class [J].

Damsky, William ;

King, Brett A. .

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2017, 76 (04) :736-744

[5] JAK3 as an Emerging Target for Topical Treatment of Inflammatory Skin Diseases [J].

de Medeiros, Ana Karina Alves ;

Speeckaert, Reinhart ;

Desmet, Eline ;

Van Gele, Mireille ;

De Schepper, Sofie ;

Lambert, Jo .

PLOS ONE, 2016, 11 (10)

[6] Janus kinases in immune cell signaling [J].

Ghoreschi, Kamran ;

Laurence, Arian ;

O'Shea, John J. .

IMMUNOLOGICAL REVIEWS, 2009, 228 :273-287

[7] Oral ruxolitinib induces hair regrowth in patients with moderate-to-severe alopecia areata [J].

Mackay-Wiggan, Julian ;

Jabbari, Ali ;

Nhan Nguyen ;

Cerise, Jane E. ;

Clark, Charlotte ;

Ulerio, Grace ;

Furniss, Megan ;

Vaughan, Roger ;

Christiano, Angela M. ;

Clynes, Raphael .

JCI INSIGHT, 2016, 1 (15)

[8] The JAK-STAT Pathway: Impact on Human Disease and Therapeutic Intervention [J].

O'Shea, John J. ;

Schwartz, Daniella M. ;

Villarino, Alejandro V. ;

Gadina, Massimo ;

McInnes, Iain B. ;

Laurence, Arian .

ANNUAL REVIEW OF MEDICINE, VOL 66, 2015, 66 :311-328

[9] MECHANISMS OF DISEASE JAKs and STATs in Immunity, Immunodeficiency, and Cancer [J].

O'Shea, John J. ;

Holland, Steven M. ;

Staudt, Louis M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2013, 368 (02) :161-170

[10] An insight into JAK-STAT signalling in dermatology [J].

Palanivel, J. A. ;

Macbeth, A. E. ;

Chetty, N. C. ;

Levell, N. J. .

CLINICAL AND EXPERIMENTAL DERMATOLOGY, 2014, 39 (04) :513-518